A Good Day for Cannasouth as Share Value Skyrockets by Over 13%

Cannasouth Ltd [NZX:CBD] has benefited from bullish trading today, experiencing a sharp jump of 13.46%.

Cannasouth is a biopharmaceutical company that specialises researching and developing medicinal cannabis. It is the first of its kind to list on the New Zealand Stock Exchange.

At the time of writing, Cannasouth has a market capitalisation of $47 million, and the share price sits at $0.59.

Why has the [NZX:CBD] share price increased today?

The market sentiment was enthusiastic today when Cannasouth released a positive statement that bode well for the future of the company.

Here are some key takeaways:

  • Cannasouth has experienced has strong growth in investment —boosting its shareholder base from 1450 to over 2000 since its IPO.
  • Cannasouth has made a submission to the New Zealand government, calling for additional support to the Medicinal Cannabis Scheme. If successful, this could open up fresh doors for business expansion .

Naturally enough, these developments have been received warmly by investors, driving a higher demand for Cannasouth shares.

Where could [NZX:CBD] go from here?

Cannasouth remains a small-cap stock with significant risk and speculation involved.

However, if the New Zealand government accepts Cannasouth’s proposal for more flexible medicinal cannabis regulation, this will almost certainly boost Cannasouth prospects for growth.

No one has a crystal ball at this point. It’s still a case of wait and see.

Regards,

John Ling,
Contributor, WealthMorning.com

Daily Wealth

Subscribe now to get our members-only podcast — ‘Property at a 50% Discount: The Most Explosive Investment Trend in a Generation’ — and receive the investor’s newsletter capturing the most decisive financial events that could impact your wealth.

By clicking Subscribe you agree you’ve read and accepted our Privacy Policy. You can cancel at any time.


John is the Chief Marketing Officer at Wealth Morning. His responsibilities include marketing, customer service, and compliance. He is an experienced investor and portfolio manager, trading both on his own account and assisting with high net-worth clients. In addition to contributing financial and geopolitical articles to this site, John is a bestselling author in his own right. His international thrillers have appeared on the USA Today and Amazon bestseller lists. John is a shareholder of Wealth Morning.


Wealth Morning Stock Market News, Finance and Investments